Cantor Fitzgerald Reiterates Overweight Rating for Kura Oncology (NASDAQ:KURA)

Kura Oncology (NASDAQ:KURA – Get Free Report)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday,Benzinga reports. Several other research firms also recently issued reports on KURA. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a report on […]

Leave a Reply

Your email address will not be published.

Previous post Pfizer Inc. (NYSE:PFE) Shares Bought by Integrated Investment Consultants LLC
Next post 2024 Volvo V60 Cross Country B5 AWD Ultimate Review & Test Drive